Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureBradley Tucker, Kwok Leung Ong, Thomas Payne, Kristy P. Robledo, Anthony Keech, Sanjay Patel
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
10.1093/eurheartj/ehab309 · 2021
Inflammation, cholesterol, Lipoprotein(a), and 30-Year cardiovascular outcomes in women
10.1056/nejmoa2405182 · 2024
Interleukin-6 signaling and Anti-Interleukin-6 therapeutics in cardiovascular disease
10.1161/circresaha.121.319077 · 2021
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis
10.1016/s0140-6736(09)61717-7 · 2010
Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein
10.1056/nejmoa0807646 · 2008
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
10.1016/s0140-6736(17)32814-3 · 2018
The efficacy and safety of low dose colchicine in atherosclerotic cardiovascular disease - a systematic review and meta-analysis
2025
Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association
10.1161/atv.0000000000000147 · 2022
datacite
Confidence 0%
Lipoprotein(a) as a pharmacological target: premises, promises, and prospects
10.1161/circulationaha.124.069210 · 2025
Risk assessment for cardiovascular disease with nontraditional risk factors: US preventive services task force recommendation statement
10.1001/jama.2018.8359 · 2018
Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK biobank
10.1016/j.atherosclerosis.2023.117437 · 2024
Lipoprotein(a), C-Reactive protein, and cardiovascular risk in primary and secondary prevention populations
10.1001/jamacardio.2023.5605 · 2024
10.1161/circulationaha.124.071269
10.1161/circulationaha.124.071269 · 2025
10.1093/eurheartj/ehab484
10.1093/eurheartj/ehab484 · 2021
UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age
10.1371/journal.pmed.1001779 · 2015
The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
10.1016/s0140-6736(07)61602-x · 2007
C-Reactive protein and risk of incident heart failure in patients with cardiovascular disease
10.1016/j.jacc.2023.05.035 · 2023
Unresolved referenced work
2019
Unresolved referenced work
2022
Causes of death in people with cardiovascular disease: a UK biobank cohort study
10.1161/jaha.121.023188 · 2021
Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2
10.1093/eurjpc/zwad187 · 2023
Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use
10.1186/s41073-016-0007-6 · 2016
Prognostic impact of high-sensitivity C-Reactive protein in patients undergoing percutaneous coronary intervention according to BMI
10.1016/j.jcin.2020.09.024 · 2020
Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events
10.1093/eurheartj/ehaf281 · 2025
How to interpret statistical models using marginaleffects for R and python
10.18637/jss.v111.i09 · 2024
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
10.1016/s0140-6736(23)00215-5 · 2023
Low-dose colchicine for secondary prevention of coronary artery disease
10.1016/j.jacc.2023.05.055 · 2023
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis society consensus statement
10.1093/eurheartj/ehac361 · 2022
Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank
10.1161/atvbaha.120.315291 · 2021
Lipoprotein(a) for risk assessment in patients with established coronary artery disease
10.1016/j.jacc.2013.09.042 · 2014
Association of Lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial
10.1001/jamacardio.2017.3833 · 2018
Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database
10.1093/eurheartj/ehaf297 · 2025
Sex differences in the intensity of statin prescriptions at initiation in a primary care setting
10.1136/heartjnl-2023-323722 · 2024
Sex differences in the use of statins in community practice
2019
Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-norfolk study
10.1093/eurheartj/ehaf209 · 2025
Association of Lipoprotein(a) and Interleukin-6 with cardiovascular risk: MESA and UK biobank
10.1016/j.jacc.2025.08.101 · 2025
Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER study
10.1373/clinchem.2008.120642 · 2009
No additional external references are available.